Cargando…

Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson’s Disease

Levodopa (LD) is the most effective drug in the treatment of Parkinson’s disease (PD). However, although it represents the “gold standard” of PD therapy, LD can cause side effects, including gastrointestinal and cardiovascular symptoms as well as transient elevated liver enzyme levels. Moreover, LD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bello, Fabio Del, Giannella, Mario, Giorgioni, Gianfabio, Piergentili, Alessandro, Quaglia, Wilma
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6523988/ https://www.ncbi.nlm.nih.gov/pubmed/30970612 http://dx.doi.org/10.3390/biom9040142

Ejemplares similares

Scaffold Hybridization Strategy Leads to the Discovery of Dopamine D(3) Receptor-Selective or Multitarget Bitopic Ligands Potentially Useful for Central Nervous System Disorders
por: Bonifazi, Alessandro, et al.
Publicado: (2021)

Synthesis and Cytotoxic Activity Evaluation of New Cu(I) Complexes of Bis(pyrazol-1-yl) Acetate Ligands Functionalized with an NMDA Receptor Antagonist
por: Pellei, Maura, et al.
Publicado: (2020)

Advances in the Development of Nonpeptide Small Molecules Targeting Ghrelin Receptor
por: Giorgioni, Gianfabio, et al.
Publicado: (2022)

Underlying Susceptibility to Eating Disorders and Drug Abuse: Genetic and Pharmacological Aspects of Dopamine D4 Receptors
por: Botticelli, Luca, et al.
Publicado: (2020)

Novel Potent Muscarinic Receptor Antagonists: Investigation on the Nature of Lipophilic Substituents in the 5- and/or 6-Positions of the 1,4-Dioxane Nucleus
por: Del Bello, Fabio, et al.
Publicado: (2020)

Novel Highly Potent and Selective Sigma1 Receptor Antagonists Effectively Block the Binge Eating Episode in Female Rats
por: Cifani, Carlo, et al.
Publicado: (2020)

Highly Potent and Selective Dopamine D(4) Receptor Antagonists Potentially Useful for the Treatment of Glioblastoma
por: Pavletić, Pegi, et al.
Publicado: (2022)

Cu(I) and Cu(II) Complexes Based on Lonidamine-Conjugated Ligands Designed to Promote Synergistic Antitumor Effects
por: Del Bello, Fabio, et al.
Publicado: (2022)

Properly Substituted Benzimidazoles as a New Promising Class of Nicotinate Phosphoribosyltransferase (NAPRT) Modulators
por: Baldassarri, Cecilia, et al.
Publicado: (2023)

L-DOPA Is an Endogenous Ligand for OA1
por: Lopez, Vanessa M, et al.
Publicado: (2008)

L-DOPA-therapy in Parkinson’s disease: some personal reflections on L-DOPA therapy from Vienna and Berlin
por: Riederer, Peter, et al.
Publicado: (2023)

Molecular Effects of L-dopa Therapy in Parkinson’s Disease
por: Dorszewska, Jolanta, et al.
Publicado: (2014)

Beyond L-DOPA: hope for Parkinson’s treatment and diagnosis
Publicado: (2017)

Polymorphisms of Dopamine Receptor Genes and Risk of L-Dopa–Induced Dyskinesia in Parkinson’s Disease
por: Comi, Cristoforo, et al.
Publicado: (2017)

l-DOPA and Its Receptor GPR143: Implications for Pathogenesis and Therapy in Parkinson’s Disease
por: Goshima, Yoshio, et al.
Publicado: (2019)

Dopamine D3 Receptor Plasticity in Parkinson’s Disease and L-DOPA-Induced Dyskinesia
por: Lanza, Kathryn, et al.
Publicado: (2021)

L-DOPA
por: Hornykiewicz, Oleh
Publicado: (2017)

Parkinson’s disease, L-DOPA, and endogenous morphine: A revisit
por: Stefano, George B., et al.
Publicado: (2012)

L-DOPA in Parkinson’s Disease: Looking at the “False” Neurotransmitters and Their Meaning
por: Chagraoui, Abdeslam, et al.
Publicado: (2019)

Altered cerebellar connectivity in Parkinson's patients ON and OFF L-DOPA medication
por: Festini, Sara B., et al.
Publicado: (2015)

The Design and Evaluation of an l-Dopa–Lazabemide Prodrug for the Treatment of Parkinson’s Disease
por: Hoon, Monique, et al.
Publicado: (2017)

Inhaling xenon ameliorates l‐dopa‐induced dyskinesia in experimental parkinsonism
por: Baufreton, Jérôme, et al.
Publicado: (2018)

An Integrative Approach to Treat Parkinson's Disease: Ukgansan Complements L-Dopa by Ameliorating Dopaminergic Neuronal Damage and L-Dopa-Induced Dyskinesia in Mice
por: Huh, Eugene, et al.
Publicado: (2019)

L-Dopa and Behavior
por: Kebabian, John
Publicado: (1974)

Readiness Potential in Parkinson's Disease: Effects of L-Dopa Therapy and Brain Transplants
por: Martínez, D. N. Velázquez, et al.
Publicado: (1992)

The role of GRK6 in animal models of Parkinson's Disease and L-DOPA treatment
por: Managò, Francesca, et al.
Publicado: (2012)

L-DOPA-Induced Dyskinesia in a Genetic Drosophila Model of Parkinson’s Disease
por: Blosser, Joshua A., et al.
Publicado: (2020)

Individual Magnetoencephalography Response Profiles to Short-Duration L-Dopa in Parkinson’s Disease
por: Peña, Edgar, et al.
Publicado: (2021)

Differential Dopamine Receptor Occupancy Underlies L-DOPA-Induced Dyskinesia in a Rat Model of Parkinson's Disease
por: Sahin, Gurdal, et al.
Publicado: (2014)

l-DOPA and Freezing of Gait in Parkinson’s Disease: Objective Assessment through a Wearable Wireless System
por: Suppa, Antonio, et al.
Publicado: (2017)

Novel anti-apoptotic L-DOPA precursors SuperDopa and SuperDopamide as potential neuroprotective agents for halting/delaying progression of Parkinson’s disease
por: Wiesen, Tom, et al.
Publicado: (2022)

L-Dopa and the Albino Riddle: Content of L-Dopa in the Developing Retina of Pigmented and Albino Mice
por: Roffler-Tarlov, Suzanne, et al.
Publicado: (2013)

L-dopa treatment increases oscillatory power in the motor cortex of Parkinson's disease patients
por: Cao, Chunyan, et al.
Publicado: (2020)

Radiation-induced Brain Calcification Leads to L-dopa-resistant Parkinsonism and Cerebellar Ataxia
por: Shimada, Tomoyo, et al.
Publicado: (2022)

Curcumin modulation of L-dopa and rasagiline-induced neuroprotection in rotenone model of Parkinson’s disease
por: El-Shamarka, Marwa El-Sayed, et al.
Publicado: (2023)

Behavioral effects of zonisamide on L-DOPA-induced dyskinesia in Parkinson's disease model mice
por: Sano, Hiromi, et al.
Publicado: (2023)

RasGRP1 is a causal factor in the development of l-DOPA–induced dyskinesia in Parkinson’s disease
por: Eshraghi, Mehdi, et al.
Publicado: (2020)

Cross-talk between alpha(1D)-adrenoceptors and transient receptor potential vanilloid type 1 triggers prostate cancer cell proliferation
por: Morelli, Maria Beatrice, et al.
Publicado: (2014)

Dopa Responsive Slow Orthostatic Tremor in Parkinson’s Disease
por: Lee, Suk Yoon, et al.
Publicado: (2011)

Predictors of Levo-dopa induced Dyskinesias in Parkinson's Disease
por: Athulya, RT, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_eqdo9vhhtn3vgj5254b5d1dv9n